Health

Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020

Wednesday, September 23, 2020 - 1:10am

The primary endpoint is ORR per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR).

Key Points: 
  • The primary endpoint is ORR per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR).
  • Secondary endpoints include progression-free survival (PFS) and
    duration of response (DOR) per RECIST v1.1 by BICR, overall survival (OS) and safety.
  • At data cutoff (June 10, 2020), a total of 103 patients were enrolled and treated.
  • LEAP-005 (ClinicalTrials.gov, NCT03797326) is a Phase 2, single-arm, open-label trial evaluating LENVIMA in combination with KEYTRUDA in patients with select previously treated advanced solid tumors.

Sperm Bank Market: COVID-19 Business Continuity Plan | Evolving Opportunities with Androcryos and Cryos International-Denmark ApS | Technavio

Wednesday, September 23, 2020 - 1:45am

Cryos International-Denmark ApS provides services such as sperm storage and supplies frozen donor sperm and eggs globally.

Key Points: 
  • Cryos International-Denmark ApS provides services such as sperm storage and supplies frozen donor sperm and eggs globally.
  • The company offers sperm bank services such as sperm storage, sperm analysis service and consultations services
    European Sperm Bank ApS focuses on the business of cryopreservation of human cells and tissues, and offers services such as sperm storage, sperm donors, photo matching services, screening of genes, etc.
  • The company offers sperm bank and associated services such as cryogenic sperm storage assistance in sperm donotions, photo matching services, screening of genes etc.
  • The company offers sperm bank services such as sperm storage and sperm analysis service.

Smart Baby Thermometers Market: COVID-19 Business Continuity Plan | Evolving Opportunities with B. Braun Melsungen AG and Briggs Corp. | Technavio

Wednesday, September 23, 2020 - 1:00am

In addition, the compatibility with mobile operating systems is anticipated to boost the growth of the Smart Baby Thermometers Market.

Key Points: 
  • In addition, the compatibility with mobile operating systems is anticipated to boost the growth of the Smart Baby Thermometers Market.
  • The increased adoption of smart products corresponds to the high demand for smart baby thermometers as well.
  • Major Five Smart Baby Thermometers Companies:
    B. Braun Melsungen AG has business operations under four segments: B. Braun Hospital Care, B. Braun Aesculap, B. Braun Out Patient Market, and B. Braun Avitum.
  • Smart Baby Thermometers Market Product Outlook (Revenue, USD mn, 2020-2024)
    Smart Baby Thermometers Market Regional Outlook (Revenue, USD mn, 2020-2024)
    Are you a start-up willing to make it big in the business?

EU financial regulators assess risks to the financial sector after the outbreak of COVID-19 and call for enhanced cooperation

Wednesday, September 23, 2020 - 12:06am

The Report highlights how the pandemic has led to further amplified profitability concerns across the board and heightened liquidity challenges in segments of the investment fund sector.

Key Points: 
  • The Report highlights how the pandemic has led to further amplified profitability concerns across the board and heightened liquidity challenges in segments of the investment fund sector.
  • It particularly points to economic and market uncertainty as a key challenge going forward.
  • The impact of the crisis on EU banks asset quality is a key concern as significant uncertainty about the timing and size of a recovery persists.
  • Directly following the COVID-19 outbreak in Europe, the ESAs actions provided for regulatory flexibility, fostered operational resilience, and highlighed the importance of consumer protection.

Press release - COVID-19 vaccines: MEPs seek answers from industry representatives

Wednesday, September 23, 2020 - 12:06am

MEPs highlighted the challenge of ensuring that vaccines are available as soon as possible, while at the same time building public trust in vaccination.

Key Points: 
  • MEPs highlighted the challenge of ensuring that vaccines are available as soon as possible, while at the same time building public trust in vaccination.
  • We wanted to have more information on the state of research, the commitments made by laboratories, and whether they will be able to meet them.
  • The lack of transparency surrounding these contracts was very clearly highlighted during this hearing where Parliament played a role in ensuring democratic accountability, he added.
  • During the debate, industry representatives from Sanofi and Curevac reiterated their commitments to produce one billion doses in 2021, and the importance of keeping safety first.

Laird Superfood Announces Pricing of Initial Public Offering

Tuesday, September 22, 2020 - 11:53pm

Laird Superfood, Inc. (Laird Superfood) today announced the pricing of its initial public offering of 2,650,000 shares of its common stock at a price of $22.00 per share.

Key Points: 
  • Laird Superfood, Inc. (Laird Superfood) today announced the pricing of its initial public offering of 2,650,000 shares of its common stock at a price of $22.00 per share.
  • Laird Superfood has granted the underwriters a 30-day option to purchase up to an additional 397,500 shares of its common stock to cover over allotments, if any, at the initial public offering price, less underwriting discounts and commissions.
  • Canaccord Genuity and Craig-Hallum Capital Group are acting as the joint book-running managers for the offering.
  • Laird Superfood, Inc. creates award-winning, plant-based superfood products that are both delicious and functional.

Phytech Raises $23.5 Million in Growth Funding From THL Automation Fund and Existing Anchor Investors

Tuesday, September 22, 2020 - 11:38pm

Under the terms of the agreement, funds managed by THL, including THL Automation Fund L.P., and existing anchor investors will invest $23.5 million to support growth of the Company.

Key Points: 
  • Under the terms of the agreement, funds managed by THL, including THL Automation Fund L.P., and existing anchor investors will invest $23.5 million to support growth of the Company.
  • THL Managing Director Josh Bresler has joined the Phytech board of directors as part of the transaction.
  • Phytech helps farmers harness the power of digital farming in optimizing production and transforming operations by connecting them directly to their plants.
  • Listening closely to our customers, this funding will serve primarily to add needed automation capabilities and support our global market expansion.

MEDISCA Retains Position as Industry Leader and Innovator for Planetary Mixers via Its Patent Portfolio.

Tuesday, September 22, 2020 - 11:21pm

Prior to launching the product, MEDISCA spent two years researching asymmetrical technology and best practices for compounding pharmacy needs.

Key Points: 
  • Prior to launching the product, MEDISCA spent two years researching asymmetrical technology and best practices for compounding pharmacy needs.
  • After successfully implementing and developing proprietary know-how, MEDISCA spent five years rigorously testing and troubleshooting hundreds of formulas, in order to properly integrate this technology into compounding pharmacy.
  • There are several key elements that differentiate the MAZ mixer from other planetary mixers on the market, including the ability to melt the contents during the mixing process.
  • When a client buys a product from MEDISCA, they can expect exceptional quality, unparalleled customer service, and problem-solving innovation, said Panagiota Danopoulos, Senior Vice President at MEDISCA.

Indee Labs Awarded Contract from the National Cancer Institute

Tuesday, September 22, 2020 - 11:19pm

Indee Labs is a biotechnology company developing the VS Delivery SystemTM for non-viral intracellular or gene delivery.

Key Points: 
  • Indee Labs is a biotechnology company developing the VS Delivery SystemTM for non-viral intracellular or gene delivery.
  • The team at Indee Labs was recently awarded a contract from the National Cancer Institute to develop the VS Delivery SystemTM for T cell immunotherapy discovery, development and manufacturing.
  • This project has been funded in whole with Federal funds ($399,299.00) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No.
  • Indee Labs is backed by IndieBio/SOSV, Y Combinator, Social Capital, Main Sequence Ventures, Founders Funds FF Science among others.

EU financial regulators assess risks to the financial sector after the outbreak of COVID-19 and call for enhanced cooperation

Wednesday, September 23, 2020 - 12:04am

The Report highlights how the pandemic has led to further amplified profitability concerns across the board and heightened liquidity challenges in segments of the investment fund sector.

Key Points: 
  • The Report highlights how the pandemic has led to further amplified profitability concerns across the board and heightened liquidity challenges in segments of the investment fund sector.
  • It particularly points to economic and market uncertainty as a key challenge going forward.
  • The impact of the crisis on EU banks asset quality is a key concern as significant uncertainty about the timing and size of a recovery persists.
  • Directly following the COVID-19 outbreak in Europe, the ESAs actions provided for regulatory flexibility, fostered operational resilience, and highlighed the importance of consumer protection.